thrombopoietin receptor agonists in itp: current status and future outlooks
Published 1 year ago • 372 plays • Length 3:17Download video MP4
Download video MP3
Similar videos
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
1:32
shifting the treatment landscape of itp: novel agents and future outlooks
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
3:11
the therapeutic implications of shared pathophysiology in classical itp and other thrombocytopenias
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
1:09
emerging treatment options for refractory immune thrombocytopenia
-
2:38
the management of itp during and after the covid-19 pandemic
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
15:24
idiopathic thrombocytopenic purpura (itp) #cme #internal_medicine #medical #usmle #محاضرات_باطنة
-
2:41
bomedemstat combined with ruxolitinib for the treatment of mf: early results of a phase ii trial
-
3:41
treatment of anemia in lr-mds: luspatercept and imetelstat
-
1:26
avatrombopag, rilzabrutinib and covid-19 updates in itp
-
1:55
latest updates in the management of immune thrombocytopenia
-
1:05
hematological predictors of thrombotic risk or disease progression in essential thrombocythemia
-
1:34
are thrombotic risk and progression in et predictable?
-
1:09
challenges associated with managing chemotherapy-induced thrombocytopenia
-
1:15
immune thrombocytopenic purpura - an osmosis preview
-
4:20
itp update: diagnosis, treatment & covid-19 vaccines
-
2:28
investigating the impact of pacritinib on survival in patients with mf and severe thrombocytopenia
-
2:03
unmet needs in immune thrombocytopenia
-
27:49
tpo agents beyond itp
-
1:53
immune thrombocytopenic purpura (itp) - causes, pathogenesis, signs & symptoms, diagnosis, treatment